• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Nov. 14

The board of directors of Aurobindo Pharma Ltd has decided to divest its entire shareholding in the China-based wholly owned subsidiary - Aurobindo Tongling (Datong) Pharmaceutical Company Ltd. The board, at its meeting on Tuesday, also decided to acquire Senor Organics Pvt Ltd, a Hyderabad-based profit making and small-sized pharma company into bulk drug intermediates.

The company has informed the stock exchanges that the board has authorised the Managing Director to negotiate and finalise the above deals, subject to statutory compliances. When contacted, a senior company official told Business Line that the company had decided to divest holding in Chinese venture since the venture was incurring losses and operations were not proving remunerative.

The company was in favour of shifting the focus of its global operations more towards remunerative markets such as the US and Europe, he said. The Chinese pharma subsidiary suffered a loss of Rs 6.55 crore on a turnover of Rs 131.01 crore. As on March, the company's total assets stood at Rs 126.98 crore, while the liabilities amounted to Rs 108.85 crore.

More Stories on : Overseas Investments | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Piaggio set to roll out LCV in January

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line